Impact of prescription drugs on second fragility fractures among US Medicare patients.

Osteoporos Int. 2018 Sep 19. doi: 10.1007/s00198-018-4697-0.

DOI: 10.1007/s00198-018-4697-0

PMID: 30232537

Munson JC(1)(2)(3), Bynum JPW(4)(5)(6)(7), Bell JE(4)(8), McDonough C(9), Wang Q(4), Tosteson T(4)(10), Tosteson ANA(4)(5).

https://www.ncbi.nlm.nih.gov/pubmed/30232537

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro